ABIOMED, Inc. (NASDAQ:ABMD) has been assigned an average rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $193.83.

Several equities analysts have recently commented on the stock. BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research note on Tuesday, November 7th. Jefferies Group reissued a “buy” rating and issued a $175.00 price target on shares of ABIOMED in a research note on Tuesday, August 29th. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Piper Jaffray Companies increased their price target on shares of ABIOMED to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, October 26th.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total transaction of $1,910,268.24. The disclosure for this sale can be found here. Insiders have sold 27,646 shares of company stock valued at $4,836,333 in the last ninety days. Insiders own 7.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Lord Abbett & CO. LLC boosted its holdings in ABIOMED by 282.5% in the second quarter. Lord Abbett & CO. LLC now owns 60,882 shares of the medical equipment provider’s stock worth $8,724,000 after purchasing an additional 44,967 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in ABIOMED by 16.2% in the second quarter. Eagle Asset Management Inc. now owns 227,467 shares of the medical equipment provider’s stock worth $32,596,000 after purchasing an additional 31,690 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in ABIOMED by 21.7% in the second quarter. Victory Capital Management Inc. now owns 9,761 shares of the medical equipment provider’s stock worth $1,399,000 after purchasing an additional 1,738 shares during the last quarter. State of Tennessee Treasury Department purchased a new stake in ABIOMED in the third quarter worth approximately $5,058,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in ABIOMED by 45.3% in the second quarter. BNP Paribas Arbitrage SA now owns 16,206 shares of the medical equipment provider’s stock worth $2,322,000 after purchasing an additional 5,055 shares during the last quarter. Hedge funds and other institutional investors own 90.45% of the company’s stock.

Shares of ABIOMED (ABMD) opened at $193.69 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84. ABIOMED has a 1 year low of $103.53 and a 1 year high of $200.28. The stock has a market cap of $8,573.07, a PE ratio of 124.29, a price-to-earnings-growth ratio of 2.58 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.38 by $0.16. The firm had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. equities research analysts anticipate that ABIOMED will post 2.38 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/21/abiomed-inc-abmd-given-average-rating-of-buy-by-analysts.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.